1. Lipids, the Heart, and the Kidney

3. Relationship Between CKD and CVD

4. CKD Burden and Severity Increase With Age

5. CVD Risk Increases With Renal Impairment

6. CV Mortality Is Higher in Patients With ESRD

7. CV Mortality General Population vs Dialysis or Transplant Patients

8. Mechanism of CVD Development in Patients With Uremia

9. Lipid-Lowering Therapy Should Be Used Routinely in Patients With CKD

10. SHARP Trial Simvastatin Plus Ezetimibe in CKD and Dialysis Patients

11. NKF KDOQI Guidelines and the 2010 CVD and CKD Core Curriculum Management of Dyslipidemia

12. CKD Is a Risk Enhancer for CVD ACC/AHA 2018 Guidelines

13. CKD Is a Disease Multiplier

14. Statin AEs

15. IMPROVE-IT Subanalysis of Outcomes and AEs in Patients With DM

16. PCSK9 Inhibitor Therapy FOURIER CKD Subanalysis

17. FOURIER CKD Subanalysis Baseline Characteristics by CKD Stage

18. FOURIER CKD Subanalysis Change in LDL

19. FOURIER CKD Subanalysis Baseline Characteristics by CKD Stage (cont)

20. FOURIER CKD Subanalysis Event Rates by CKD Stage

21. FOURIER CKD Subanalysis Additional Events by CKD Stage

22. FOURIER CKD Subanalysis Safety by CKD Stage

23. FOURIER CKD Subanalysis Key Secondary Endpoint

24. FOURIER CKD Subanalysis Overall CKD Progression and Change in eGFR

25. Alirocumab ODYSSEY Outcomes Trial Results

26. CKD Stages and Associated Clinical Events

27. Strategies for Collaborative Patient-Centered Care in Patients With CKD

28. Conclusion

29. Abbreviations

30. Abbreviations (cont)

31. Abbreviations (cont)

32. Abbreviations (cont)